Secondary Logo

Journal Logo

Most Popular Articles

Sentinel Node Biopsy Imaging in Breast Cancer: Scatter Reduction Using 3-Dimensionally Printed Lead Shields

Cañete-Sánchez, Francisco M.; Boulvard-Chollet, Xavier L. E.; Chamorro, Xabier; More

Clinical Nuclear Medicine. 47(7):618-624, July 2022.

Detecting Interval Distant Metastases With 18F-FDG PET/CT After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer

Kroese, Tiuri E.; Ruurda, Jelle P.; Bakker, Anne S.; More

Clinical Nuclear Medicine. 47(6):496-502, June 2022.

PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma

Beppu, Takaaki; Iwaya, Takeshi; Sato, Yuichi; More

Clinical Nuclear Medicine. 47(7):569-574, July 2022.

Evaluation of the Hybrid Tracer Indocyanine Green–99mTc-Nanocolloid for Sentinel Node Biopsy in Bladder Cancer—A Prospective Pilot Study

Rietbergen, Daphne D.D.; van Gennep, Erik J.; KleinJan, Gijs H.; More

Clinical Nuclear Medicine. : June 18, 2022

Decentralized Distributed Multi-institutional PET Image Segmentation Using a Federated Deep Learning Framework

Shiri, Isaac; Vafaei Sadr, Alireza; Amini, Mehdi; More

Clinical Nuclear Medicine. 47(7):606-617, July 2022.

Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor–Directed Molecular Imaging and Therapy

Serfling, Sebastian E.; Hartrampf, Philipp E.; Zhi, Yingjun; More

Clinical Nuclear Medicine. 47(6):512-516, June 2022.

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy

Love, Charito; Desai, Neil B.; Abraham, Tony; More

Clinical Nuclear Medicine. 47(6):503-511, June 2022.

Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients

Berzaczy, Dominik; Giraudo, Chiara; Haug, Alexander R.; More

Clinical Nuclear Medicine. 42(9):669-674, September 2017.

Initial Experience Using 99mTc-MIBI SPECT/CT for the Differentiation of Oncocytoma From Renal Cell Carcinoma

Rowe, Steven P.; Gorin, Michael A.; Gordetsky, Jennifer; More

Clinical Nuclear Medicine. 40(4):309-313, April 2015.

First-in-Human Experience With 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an Uncommon Case of Aggressive Medullary Thyroid Carcinoma Clinically Mimicking as Anaplastic Thyroid Cancer

Ballal, Sanjana; Yadav, Madhav Prasad; Moon, Euy Sung; More

Clinical Nuclear Medicine. 47(6):e444-e445, June 2022.

Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells

Sesques, Pierre; Tordo, Jérémie; Ferrant, Emmanuelle; More

Clinical Nuclear Medicine. 46(8):627-634, August 2021.

Delayed [18F]-FDG PET Imaging Increases Diagnostic Performance and Reproducibility to Differentiate Recurrence of Brain Metastases From Radionecrosis

Otman, Hosameldin; Farce, Julien; Meneret, Pierre; More

Clinical Nuclear Medicine. : June 10, 2022

Role of Dynamic Parameters of 18F-DOPA PET/CT in Pediatric Gliomas

Fiz, Francesco; Bini, Fabiano; Gabriele, Edoardo; More

Clinical Nuclear Medicine. 47(6):517-524, June 2022.

Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET

Vettermann, Franziska J.; Felsberg, Jörg; Reifenberger, Guido; More

Clinical Nuclear Medicine. 43(12):895-898, December 2018.

SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer

Schmidkonz, Christian; Cordes, Michael; Beck, Michael; More

Clinical Nuclear Medicine. 43(4):225-231, April 2018.

Pharmacokinetic Studies of 68Ga-Labeled Bombesin (68Ga-BZH3) and F-18 FDG PET in Patients With Recurrent Gliomas and Comparison to Grading: Preliminary Results

Dimitrakopoulou-Strauss, Antonia; Seiz, Marcel; Tuettenberg, Jochen; More

Clinical Nuclear Medicine. 36(2):101-108, February 2011.

Show: